www.nature.com/scientificreports




                OPEN             Author Correction: DUSP5
                                 is methylated in CIMP‑high
                                 colorectal cancer but is not a
                                 major regulator of intestinal cell
                                 proliferation and tumorigenesis
                                 Lars Tögel , Rebecca Nightingale , Rui Wu , Anderly C. Chüeh , Sheren Al‑Obaidi ,
                                 Ian Luk , Mercedes Dávalos‑Salas , Fiona Chionh , Carmel Murone , Daniel D. Buchanan ,
                                 Zac Chatterton , Oliver M. Sieber , Diego Arango , Niall C. Tebbutt , David Williams ,
                                 Amardeep S. Dhillon  & John M. Mariadason
                                 Correction to: Scientific Reports https://​doi.​org/​10.​1038/​s41598-​018-​20176-9, published online 29 January 2018

                                 The Article contains an error in Figure 2, where the western blot showing tubulin has 7 lanes instead of 6 lanes.

                                 The correct Figure 2 and accompanying legend appear below




Scientific Reports |   (2023) 13:2422                | https://doi.org/10.1038/s41598-023-29328-y                                                   1

                                                                                                                                               Vol.:(0123456789)
          www.nature.com/scientificreports/




                                            Figure 2.  Induction of DUSP5 by EGFR-ERK signalling in CRC cells. Time-course showing EGF-mediated
                                            induction of (A) p-ERK1/2 and DUSP5 protein expression, and (B) DUSP5 and c-FOS gene expression in
                                            LIM1215 cells. (C) Induction of DUSP5 and c-FOS mRNA by EGF requires MEK/ERK signalling. LIM1215
                                            cells were stimulated with EGF (50 ng/ml) for 24 h in the absence or presence of the MEK inhibitor (MEKi)
                                            trametinib. *P < 0.05, **P < 0.005, *P < 0.0005.



                                                          Open Access This article is licensed under a Creative Commons Attribution 4.0 International
                                                          License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
                                            format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
                                            Creative Commons licence, and indicate if changes were made. The images or other third party material in this
                                            article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
                                            material. If material is not included in the article’s Creative Commons licence and your intended use is not
                                            permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
                                            the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/.

                                            © The Author(s) 2023




          Scientific Reports |   (2023) 13:2422 |                https://doi.org/10.1038/s41598-023-29328-y                                                 2

Vol:.(1234567890)